Korea United Pharm Exports Anticancer Drugs Worth ₩4.7B to Philippines and Vietnam
Predicted impact: Low
Export deal worth about 1.6% of last year's revenue; small and routine.
Korea United Pharm유나이티드제약
033270 · KOSPI · ₩033270 · 유나이티드제약
₩16,270▼ ₩530 (3.15%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −14.91%
STOP ₩17,030DCA3 ₩16,840DCA2 ₩16,650DCA1 ₩16,460Entry ₩16,270TP1 ₩15,890TP2 ₩15,510TP3 ₩14,940TP4 ₩14,370TP5 ₩13,240
Entry, trailing stop, targets and DCA levels of the current Squeeze! setup (paper-trading levels from a fixed rule, not advice).
- Market cap
- ₩259B
- Enterprise value
- ₩231B
- P/E
- 3.5×
- P/B
- 0.5×
- Dividend yield
- 3.7%
- ROE
- 15.1%
- Net margin
- 25.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−25.4% from the high
₩16,100Today: ₩16,270 – ₩17,030₩21,800
Returns
- 1W−7.8%
- 1M−7.7%
- 3M−6.0%
- 6M−20.4%
- YTD−14.7%
- 1Y−14.9%
- Volume today
- 136,162
- 5.8× the 20-day average
- Traded today
- ₩2.2B
- Listed shares
- 15,910,775
- EPS (12 months)
- ₩4,703
- Earnings yield 28.9%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
−3.2% on Oct 27, 2026. Trading value 5.4× its normal.
- • Foreign investors sold a net ₩496M that day
- • Buzz 67 on JONBUR: heavy trading
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Warming up- BuzzRisingBuzz 67: heavy trading.
- MomentumWeak-7.8% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Korea United Pharm stock overview
Korea United Pharm (유나이티드제약, KRX: 033270) is listed on KOSPI, in the Biotech & Pharma sector. Korean specialty pharmaceutical manufacturer focused on improved new drugs (개량신약), with key products including Silostan CR, Artmac Combigel and Gastiin CR. Its shares closed at ₩16,270 on Oct 27, 2026, down 3.15% on the day, giving it a market value of ₩259B.
Key facts
- Market cap
- ₩259B
- Sector
- Biotech & Pharma
- Latest price change
- −3.15%
- As of
- Oct 27, 2026
- Main business
- Korean specialty pharmaceutical manufacturer focused on improved new drugs (개량신약), with key products including Silostan CR, Artmac Combigel and Gastiin CR.
Quick answers about Korea United Pharm
- What does Korea United Pharm do?
- Korean specialty pharmaceutical manufacturer focused on improved new drugs (개량신약), with key products including Silostan CR, Artmac Combigel and Gastiin CR. It produces about 200 products, sells finished drugs in Korea and exports to more than 40 countries, and invests heavily in R&D and advanced manufacturing plants, including facilities for solid dosage forms, injectables and anticancer drugs.
- What is the market cap of Korea United Pharm?
- The market capitalisation of Korea United Pharm was ₩259B at the close on Oct 27, 2026.
- Who are the largest shareholders of Korea United Pharm?
- According to the latest official filings, the largest reported holders are Kang Deok-yeong (41.90%, as of Aug 11, 2026); Kang Won-ho (18.12%, as of Aug 11, 2026); National Pension Service (2.76%, as of Dec 31, 2025).
- When is the next earnings report from Korea United Pharm?
- Korean companies rarely announce results dates in advance. Based on when Korea United Pharm filed the same report in past years, its next 3q results is expected around Nov 13, 2026.
- Does the National Pension Service own Korea United Pharm?
- Yes. The National Pension Service held 2.76% of Korea United Pharm shares as of Dec 31, 2025.
Company profile
Korean specialty pharmaceutical manufacturer focused on improved new drugs (개량신약), with key products including Silostan CR, Artmac Combigel and Gastiin CR. It produces about 200 products, sells finished drugs in Korea and exports to more than 40 countries, and invests heavily in R&D and advanced manufacturing plants, including facilities for solid dosage forms, injectables and anticancer drugs.
Written by AI from the company's latest annual report.
- Korean name
- 유나이티드제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 강덕영
- Founded
- Dec 1987
- Listed
- Oct 2007
- Listed shares
- 15,910,775
- Fiscal year ends
- Month 12
- Website
- www.kup.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Change of largest shareholderAug 11, 2026
- Change in largest shareholder's holdingsAug 11, 2026
- 5%+ holding reportAug 11, 2026
- Insider shareholding reportAug 11, 2026
Titles in Korean until English translations are added.
Also known as: Korea United Pharm / 유나이티드제약 / 033270 / KRX:033270
Source: KRX statistical information